ArticlePloS one2026
Multimodal anti-Helicobacter pylori effects of Lactobacillus casei HY001: Evidence from in vitro and in vivo studies.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) is a highly pathogenic microorganism that can cause various gastric diseases. Accumulating evidences have demonstrated probiotics' potential in combating H. pylori infections. The aim of this study was to explore the effects and underlying mechanism of Lactobacillus casei (L. casei) HY001 against the gastric inflammation and gastric microbiota alteration induced by H. pylori infection. These results indicated that L. casei HY001 significantly inhibited the growth of H. pylori SS1, decreased urease activity, and exhibited strong co-aggregation properties with H. pylori SS1 in vitro experiments. Furthermore, L. casei HY001 was found to be capable of inhibiting the adhesion of H. pylori SS1 with AGS cells. Subsequently, Experiments in animals suggested L. casei HY001 alleviated gastric inflammation by inhibiting the expression of NF-κ B and reducing pro-inflammatory mediator levels (IL-8, TNF-α, IL-1β, and IL-6). Moreover, the gastric microbiota 16S rRNA gene sequencing analysis revealed that L. casei HY001 improved the structure of the gastric microbiota by modulating the abundance of Firmicutes, Bacteroidota and Proteobacteria. Meanwhile, the relative abundances of Rothia, Clostridium-sensu-stricto-1, Alistipe and Prevotellacea-UG-001 were significantly increased. In contrast, the abundances of Helicobacter, Turicibacter, unclassified - Muribaculaceae, unclassified- Oscillospiraceae and Lachnospiraceae -NK4A136-group were significantly reduced following HY001 intervention. These researches indicated that L. casei HY001 improved H. pylori SS1 induced gastric mucosal damage in mice, regulated immune factors, enhanced the reduced diversity of gastric Lachnospiraceae microbiota caused by H. pylori infection, and restored the stability of the microbial community structure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.